A Safety And Efficacy Study Of Alg-1001 In Human Subjects With Symptomatic Focal Vitreomacular Adhesion

Trial Profile

A Safety And Efficacy Study Of Alg-1001 In Human Subjects With Symptomatic Focal Vitreomacular Adhesion

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jul 2015

At a glance

  • Drugs ALG 1001 (Primary)
  • Indications Macular degeneration
  • Focus Therapeutic Use
  • Sponsors Allegro Ophthalmics
  • Most Recent Events

    • 13 Jul 2015 Primary endpoint has been met. (Release of Vitreo Macular Adhesion (VMA) by Optical Coherence Tomography (OCT)), as reported by an Allegro Ophthalmics media release.
    • 13 Jul 2015 Top-line results published in the Allegro Ophthalmics Media Release.
    • 23 Jun 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top